| Filed On | Filing |
|---|---|
| 01 May 2025 |
8-K/A: Results of Operations and Financial Condition
Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 |
| 07 Sep 2023 |
8-K/A: Financial Statements and Exhibits
On August 31, 2023 (the “Closing Date”), Travere Therapeutics, Inc., (“Travere” or the “Company”) completed the sale of substantially all of the assets that are primarily related to the Company’s business of development, manufacture (inc... |
| 17 Aug 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of September 1, 2022 (the “Effective Date”) and is entered into by and between Travere Therapeutics, Inc., a Delaware corporation (hereinafter the “Company”), and Christopher C... |
| 18 Nov 2020 | 8-K/A: Other Events |
| 18 Sep 2019 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 19 May 2017 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 19 May 2017 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 11 Mar 2015 | 8-K/A: Financial Statements and Exhibits |
| 14 Aug 2014 | 8-K/A: Financial Statements and Exhibits |
| 12 Jun 2014 | 8-K/A: Financial Statements and Exhibits |
| 10 Jun 2014 | 8-K/A: Financial Statements and Exhibits |
| 07 Jan 2014 | 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets |
Loading...
